Latest news

Alfasigma S.p.A., a global pharmaceutical company, today announced the completion of its previously announced licence agreement with GSK plc.

Alfasigma, a global pharmaceutical company headquartered in Italy, today announced that it has entered into an agreement for the sale of 100% of the share capital of its subsidiary Sofar S.p.A. (“Sofar”), which includes the production site in Trezzano Rosa, to Fine Foods & Pharmaceuticals N.T.M. S.p.A. (“Fine Foods”).

Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fiscal year 2025. Its results reflect a year of strategic evolution and solid performance of key brands – all contributing to market share growth.

Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, welcomes today’s decision

GSK plc (LSE/NYSE: GSK) and Alfasigma S.p.A. today announced a licence agreement under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor being developed for cholestatic pruritus in primary biliary cholangitis (PBC).

Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, and Innovative Molecules GmbH (“Innovative Molecules”), a clinical-stage biotechnology company, today announced a strategic partnership whereby Alfasigma will invest in Innovative Molecules and has obtained the exclusive worldwide license to the parenteral formulation of adibelivir (formerly IM 250) for the treatment of Herpes Simplex Virus (HSV) encephalitis, an ultra-rare and life threatening condition.